Literature DB >> 31820681

Discovery of novel serine/threonine protein phosphatase 1 inhibitors from traditional Chinese medicine through virtual screening and biological assays.

Yehua Zhu1,2, Yi Gao1, Xinjie Sun1, Chao Wang1, Xiyan Rui1, Dongjuan Si1, Junru Zhu1, Wei Li1,3,4, Jian Liu1,3,4.   

Abstract

Protein phosphatase 1 (PP1) is a critical regulator of several processes, such as muscle contraction, neuronal signaling, glycogen synthesis, and cell proliferation. Dysregulation of PP1 has recently been found to be implicated in cardiac dysfunctions, which indicates that PP1 could be an attractive therapeutic target. However, discovery of PP1 inhibitors with satisfied safety and efficiency is still a challenge. Here, in order to discover potential PP1 inhibitors, compounds extracted from traditional Chinese medicine (TCM) were screened by a novel integrated virtual screening protocol including pharmacophore modeling and docking approaches. Combined with protein phosphatase inhibition assay, ZINC43060554 showed strongly inhibitory activity with IC50 values of 26.78 μM. Furthermore, molecular dynamics simulation and Molecular Mechanics/Generalized Born Surface Area binding free-energy analysis were performed to examine the stability of ligand binding modes. These novel scaffolds discovered in the present study can be used for rational design of PP1 inhibitors with high affinity.Communicated by Ramaswamy H. Sarma.

Entities:  

Keywords:  Protein phosphatase 1; molecular docking; molecular dynamics simulations; pharmacophore model; virtual screening

Mesh:

Substances:

Year:  2019        PMID: 31820681     DOI: 10.1080/07391102.2019.1702588

Source DB:  PubMed          Journal:  J Biomol Struct Dyn        ISSN: 0739-1102


  2 in total

1.  Exploring the dynamic mechanism of allosteric drug SHP099 inhibiting SHP2E69K.

Authors:  Xin-Hua Lu; Wei-Ya Li; Shan Du; Li-Peng Li; Yang-Chun Ma; Liang Zhou; Jing-Wei Wu; Ying Ma; Run-Ling Wang
Journal:  Mol Divers       Date:  2021-01-03       Impact factor: 2.943

2.  RIPK3-Mediated Necroptosis in Diabetic Cardiomyopathy Requires CaMKII Activation.

Authors:  Yun Chen; Xinshuai Li; Yuyun Hua; Yue Ding; Guoliang Meng; Wei Zhang
Journal:  Oxid Med Cell Longev       Date:  2021-06-07       Impact factor: 6.543

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.